Literature DB >> 1370821

A 130-kDa protein on endothelial cells binds to amino acids 15-42 of the B beta chain of fibrinogen.

J K Erban1, D D Wagner.   

Abstract

Factors which stimulate the release of von Willebrand factor (vWf) from endothelial cell Weibel-Palade bodies and which induce the expression of the leukocyte-binding adhesion molecule P-selectin (PADGEM, GMP-140, CD62) on the endothelial cell surface remain incompletely characterized. Fibrin but not fibrinogen is a potent stimulus for the release of stored von Willebrand factor from endothelial cells. Removal of fibrinopeptides A and B from fibrinogen occurs during the formation of fibrin, and the removal of fibrinopeptide B is a requirement for fibrin to induce vWf secretion. The cleavage of fibrinopeptide A by reptilase enzyme forms a fibrin gel yet it is incapable of stimulating Weibel-Palade body degranulation. As a consequence of removing fibrinopeptide B, B beta 15-42 becomes the new NH2 terminus of the beta chain of fibrin. We have shown that the peptide B beta 15-42 in solution inhibits the release of vWf stimulated by fibrin. In addition, B beta 15-42 coupled to ovalbumin supports the binding and spreading of endothelial cells, while a scrambled form of this peptide coupled to the same carrier does not. We investigated whether these determinants near the amino terminus of the beta chain of fibrin bind to a specific protein on the surface of endothelial cells. A 130-kDa protein was isolated from surface-labeled human umbilical vein endothelial cells by specific binding to B beta 15-42 immobilized on Sepharose. This glycoprotein was eluted with the B beta 15-42 peptide in solution but not with the scrambled form of this peptide. The fibrin-derived peptides B beta 19-26 and B beta 37-56-cysteine were also incapable of eluting the 130-kDa protein bound to immobilized B beta 15-42 as were the arginine-glycine-aspartic acid-serine RGDS tetrapeptide and EDTA. The 130-kDa protein is recognized neither by antibodies to the known integrins found on endothelial cells nor by antibodies to CD31 (endoCAM, PECAM-1), a member of the immunoglobulin family of receptors found on endothelial cells. The beta chain of fibrin thus contains a sequence near its amino terminus which specifically binds to what is likely a novel endothelial cell surface protein. This glycoprotein may promote endothelial cell adhesion to fibrin during the wound healing process and is a candidate for a receptor involved in fibrin-mediated release of Weibel-Palade bodies from endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370821

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Fibrinopeptides A and B release in the process of surface fibrin formation.

Authors:  Tomas Riedel; Jiri Suttnar; Eduard Brynda; Milan Houska; Leonid Medved; Jan E Dyr
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

2.  The Equine PeptideAtlas: a resource for developing proteomics-based veterinary research.

Authors:  Louise Bundgaard; Stine Jacobsen; Mette A Sørensen; Zhi Sun; Eric W Deutsch; Robert L Moritz; Emøke Bendixen
Journal:  Proteomics       Date:  2014-02-16       Impact factor: 3.984

3.  Fibrin II induces endothelial cell capillary tube formation.

Authors:  D G Chalupowicz; Z A Chowdhury; T L Bach; C Barsigian; J Martinez
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

4.  Mycoplasma suis infection results endothelial cell damage and activation: new insight into the cell tropism and pathogenicity of hemotrophic mycoplasma.

Authors:  Albina Sokoli; Katrin Groebel; Katharina Hoelzle; Werner M Amselgruber; José M Mateos; Mårten K J Schneider; Urs Ziegler; Kathrin M Felder; Ludwig E Hoelzle
Journal:  Vet Res       Date:  2013-02-11       Impact factor: 3.683

5.  Further characterization of the thrombasthenia-related idiotype OG. Antiidiotype defines a novel epitope(s) shared by fibrinogen B beta chain, vitronectin, and von Willebrand factor and required for binding to beta 3.

Authors:  Y Gruel; E Brojer; D J Nugent; T J Kunicki
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.